Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 143.94 USD -2.94% Market Closed
Market Cap: 19.5B USD

EV/EBITDA
Enterprise Value to EBITDA

-95.2
Current
-12.1
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-95.2
=
Enterprise Value
18.2B USD
/
EBITDA
-191.3m USD
Market Cap EV/EBITDA
US
Natera Inc
NASDAQ:NTRA
19.1B USD -95.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -212 010.6
US
Abbvie Inc
NYSE:ABBV
362.4B USD 16.8
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 16.3
US
Gilead Sciences Inc
NASDAQ:GILD
139.3B USD 11.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 25.9
US
Epizyme Inc
F:EPE
94.1B EUR -532.9
AU
CSL Ltd
ASX:CSL
122.4B AUD 17.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.9B USD 10.2
US
Seagen Inc
F:SGT
39.3B EUR -60.9
NL
argenx SE
XBRU:ARGX
33B EUR 315.6
EBITDA Growth EV/EBITDA to Growth
US
Natera Inc
NASDAQ:NTRA
Average EV/EBITDA: 59.1
Negative Multiple: -95.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 010.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.3
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
NL
argenx SE
XBRU:ARGX
315.6
166%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-62.9
2-Years Forward
EV/EBITDA
-309.2
3-Years Forward
EV/EBITDA
101.6